Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis.

Autor:	Ramirez Marquez E; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Requejo Figueroa GA; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Pappaterra-Rodriguez M; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Ayala Rodríguez SC; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Puebla G; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Nieves I; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Oliver AL; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Nov 09; Vol. 14 (11), pp. e31287. Date of Electronic Publication: 2022 Nov 09 (Print Publication: 2022).
DOI:	10.7759/cureus.31287
Abstrakt:	We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history of myasthenia gravis and was being treated with systemic corticosteroids and immunosuppressants. At presentation, her visual acuity was 20/80 OS; an examination (using fluorescein angiography) of the left fundus revealed a serous retinal detachment of the posterior pole that extended to the mid-periphery and multiple areas of leakage, which findings were consistent with CSCR. The patient also had a history of unresolved strabismic amblyopia in her right eye. The patient's CSCR was managed with one injection of intravitreal aflibercept (2 mg/0.05 mL). One month following treatment, her visual acuity improved to 20/20 OS, and the serous retinal detachment had resolved. Ten months following treatment, an examination revealed a sustained improvement, with a visual acuity of 20/20 OS. Concomitantly, the patient's amblyopic eye revealed an improved visual acuity of 20/20. Our case suggests that some cases of secondary CSCR may respond to treatment with intravitreal aflibercept. This case also suggests that the CSCR imposed a unique form of occlusion therapy that helped improve the amblyopia of the contralateral eye in this adult patient. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Ramirez Marquez et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu